GlassScriptPhysician profile
Barbara E Menzies
NPI 1144330291
$2,775.01
in general payments reported to CMS, 2019-2025
15 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $182 · 2021: $108 · 2022: $149 · 2023: $32.56 · 2024: $547 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591 · Education: $12.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.41 |
| Education | $12.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $614.52 | 2019-2025 | Zerbaxa, Pifeltro, Delstrigo |
| Abbvie INC. | $561.54 | 2019-2025 | |
| Gilead Sciences, INC. | $327.87 | 2019-2023 | |
| La Jolla Pharmaceutical Company | $226.43 | 2022-2024 | Xacduro |
| Shionogi INC | $218.19 | 2024-2025 | Fetroja |
| Insmed, INC. | $166.92 | 2024-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $133.88 | 2025 | Nuzyra |
| Melinta Therapeutics, LLC | $125.94 | 2019-2025 | Rezzayo |
| Janssen Biotech, INC. | $114.89 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $111.04 | 2019-2021 | |
| Viiv Healthcare Company | $93.80 | 2019-2025 | Cabenuva |
| Vyera Pharmaceuticals, LLC | $32.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $24.00 | 2025 | |
| Emmaus Medical, INC. | $14.28 | 2019 | |
| Dynavax Technologies Corporation | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Menzies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.